Apogee Therapeutics to Participate in Upcoming March Investor Conferences

Rhea-AI Summary

Apogee Therapeutics (Nasdaq: APGE) has announced that its management team will be participating in two major investor conferences in March 2025. The company will attend the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 2:30 p.m. ET, followed by the Leerink Global Healthcare Conference on Tuesday, March 11, 2025, at 8:40 a.m. ET.

For interested parties, both events will feature fireside chats that will be available through live and archived webcasts. These webcasts can be accessed via the News & Events page in the Investors section of the Apogee Therapeutics website, providing an opportunity for investors to gain insights into the company's developments and strategies.

News Market Reaction

-0.93%

1 alert

-0.93% News Effect

On the day this news was published, APGE declined 0.93%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

SAN FRANCISCO and BOSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE) today announced that members of management will participate at the following investor conferences.

TD Cowen 45^th Annual Health Care Conference 
Date: Tuesday, March 4, 2025
Time: 2:30 p.m. ET

Leerink Global Healthcare Conference
Date: Tuesday, March 11, 2025
Time: 8:40 a.m. ET

A live and archived webcast of the fireside chats will be available via the News & Events page in the Investors section of the Apogee Therapeutics website.

About Apogee

Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology markets, including for the treatment of atopic dermatitis, asthma, chronic obstructive pulmonary disease, eosinophilic esophagitis and other I&I indications. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. APG777, the company’s most advanced program, is being initially developed for the treatment of AD, which is the largest and one of the least penetrated I&I markets. With four validated targets in its portfolio, Apogee is seeking to achieve best-in-class efficacy and dosing through monotherapies and combinations of its novel antibodies. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care. For more information, please visit https://apogeetherapeutics.com.

Investor Contact:
Noel Kurdi
VP, Investor Relations
Apogee Therapeutics, Inc.
noel.kurdi@apogeetherapeutics.com

Media Contact:
Dan Budwick
1AB
dan@1abmedia.com

FAQ

When is Apogee Therapeutics (APGE) presenting at the TD Cowen Health Care Conference in 2025?

Apogee Therapeutics (APGE) will present at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 2:30 p.m. ET.

What time is APGE's presentation at the Leerink Global Healthcare Conference in March 2025?

APGE will present at the Leerink Global Healthcare Conference on Tuesday, March 11, 2025, at 8:40 a.m. ET.

How can investors access Apogee Therapeutics (APGE) conference presentations in March 2025?

Investors can access live and archived webcasts of APGE's fireside chats through the News & Events page in the Investors section of the Apogee Therapeutics website.

Which investor conferences will Apogee Therapeutics (APGE) attend in March 2025?

In March 2025, APGE will attend the TD Cowen 45th Annual Health Care Conference on March 4 and the Leerink Global Healthcare Conference on March 11.

What format will APGE's presentations take at the March 2025 investor conferences?

APGE's presentations at both March 2025 investor conferences will be in a fireside chat format, which will be webcast live and archived for later viewing.